Literature DB >> 26136907

Clinical analysis of a patient with a benign lesion of the pharynx misdiagnosed as functional thyroid cancer metastasis.

Renfei Wang1, Jian Tan1, Guizhi Zhang1, Qiang Jia1.   

Abstract

Papillary thyroid carcinoma (PTC) usually has a lower malignancy rate and better prognosis than other types of thyroid cancer. It tends to spread through the lymphatic system, and the percentage of lymph node metastasis to the neck is 50-70% in patients at the time of diagnosis. Iodine-131 (131I) whole-body scanning is very valuable in the diagnosis and positioning of functional metastatic lesions. However, a variety of comprehensive test results are frequently required to make an appropriate judgment. The present case report describes the case of a patient with PTC where a benign lesion of the pharynx was misdiagnosed as functional metastasis. Some remnant thyroid tissue and an abnormal accumulation of 131I in the oropharynx and at the right side of the neck were observed by 131I whole-body scanning one week after the first therapeutic dose. Following the second therapeutic dose, quasi-circular trapping of 131I by the pharynx persisted. Magnetic resonance imaging enhanced scanning of the oropharynx showed markedly uneven enhancement inside the lesion, and it was considered as a metastatic lesion. However, the serological test results of the patient revealed that there was no increase in the thyroglobulin level and did not support the diagnosis of progressive disease. Therefore, a biopsy on the lesion was conducted under local anesthesia. The histopathological examination exhibited salivary gland tissue and chronic inflammation. Thus, it was necessary to analyze the imaging results, as well as serologic testing outcomes and pathological findings comprehensively, in order to make the correct diagnosis.

Entities:  

Keywords:  false positive; functional metastasis; iodine-131 whole-body scanning; papillary thyroid carcinoma

Year:  2015        PMID: 26136907      PMCID: PMC4471682          DOI: 10.3892/etm.2015.2335

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  11 in total

1.  False positive 131I whole body scans in thyroid cancer.

Authors:  G Mitchell; B E Pratt; L Vini; V R McCready; C L Harmer
Journal:  Br J Radiol       Date:  2000-06       Impact factor: 3.039

2.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.

Authors:  R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger
Journal:  Endocr Pract       Date:  2001 May-Jun       Impact factor: 3.443

3.  The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.

Authors:  Ravinder K Grewal; R Michael Tuttle; Joseph Fox; Sunita Borkar; Joanne F Chou; Mithat Gonen; H William Strauss; Steven M Larson; Heiko Schöder
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 4.  Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie; Tiekun Ma
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

5.  Papillary thyroid carcinoma.

Authors:  I D Hay
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

Review 6.  Genetic basis and gene therapy trials for thyroid cancer.

Authors:  Hussam Al-Humadi; Apostolos Zarros; Rafal Al-Saigh; Charis Liapi
Journal:  Cancer Genomics Proteomics       Date:  2010 Jan-Feb       Impact factor: 4.069

Review 7.  A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.

Authors:  A F Leger; M Pellan; F Dagousset; A Chevalier; I Keller; J Clerc
Journal:  Br J Radiol       Date:  2005-05       Impact factor: 3.039

8.  Comparison of (123)I and (131)I for whole-body imaging in thyroid cancer.

Authors:  Salil D Sarkar; Tomy P Kalapparambath; Christopher J Palestro
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

Review 9.  Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.

Authors:  Peter Lind; Susanne Kohlfürst
Journal:  Semin Nucl Med       Date:  2006-07       Impact factor: 4.446

10.  Salivary gland injury resulting from exposure to radioactive iodine: case reports.

Authors:  Louis Mandel; Fred Liu
Journal:  J Am Dent Assoc       Date:  2007-12       Impact factor: 3.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.